ARCHIVES

Animas As Early Warning “Sentinels” Part Of DCE Study

This article is from The Cancer Letter archive.

Vol. 13 No. 31 | July 31, 1987

Download PDF Visit The Full Archive

Related Articles

Phase III Trebananib Trial Fails OS Endpoint In Recurrent Platinum-Resistant Ovarian Cancer

November 28, 2014

Agency Approves HPV Test That Detects 14 High-Risk Strains

November 25, 2011

ORI Finds Misconduct By Harvard Physician On Cancer Protocol; Two Other Cases

June 9, 1995

National Cancer Policy Board calls for public-private partnership for R&D in pediatric cancer drugs.

April 22, 2005

RFPs Available, NIH Funding Strategies

February 18, 1994

Natcher Subcommittee Objects To Budget Reductions, Squeeze From DeVita Details On Programs Being Cut

March 15, 1985